Mostrar el registro sencillo del ítem
dc.contributor.author | Hernando Polo, Susana | |
dc.contributor.author | Moreno Muñoz, Diana | |
dc.contributor.author | Rosero Rodríguez, Adriana Carolina | |
dc.contributor.author | Silva Ruiz, Jorge | |
dc.contributor.author | Rosero Rodríguez, Diana Isabel | |
dc.contributor.author | Couñago Lorenzo, Felipe | |
dc.date.accessioned | 2022-06-22T16:42:22Z | |
dc.date.available | 2022-06-22T16:42:22Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Hernando Polo, S., Moreno Muñoz, D., Rosero Rodríguez, A. C., Silva Ruiz, J., Rosero Rodríguez, D. I., & Couñago, F. (2021). Changing the History of Prostate Cancer with New Targeted Therapies. Biomedicines, 9(4), 392. https://doi.org/10.3390/biomedicines9040392 | spa |
dc.identifier.issn | 2227-9059 | |
dc.identifier.uri | http://hdl.handle.net/11268/11372 | |
dc.description.abstract | The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) is changing due to the emergence of new targeted therapies for the treatment of different molecular subtypes. Some biomarkers are described as potential molecular targets different from classic androgen receptors (AR). Approximately 20–25% of mCRPCs have somatic or germline alterations in DNA repair genes involved in homologous recombination. These subtypes are usually associated with more aggressive disease. Inhibitors of the enzyme poly ADP ribose polymerase (PARPi) have demonstrated an important benefit in the treatment of these subtypes of tumors. However, tumors that resistant to PARPi and wildtype BRCA tumors do not benefit from these therapies. Recent studies are exploring drug combinations with phosphatidylinositol-3-kinase (PI3K) or protein kinase B (AKT) inhibitors, as mechanisms to overcome resistance or to induce BRCAness and synthetic lethality. This article reviews various different novel strategies to improve outcomes in patients with prostate cancer. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.other | Neoplasias de la próstata | spa |
dc.subject.other | Antineoplásicos hormonales | spa |
dc.subject.other | Inmunoterapia | spa |
dc.title | Changing the History of Prostate Cancer with New Targeted Therapies | spa |
dc.type | article | spa |
dc.description.impact | 4.757 JCR (2021) Q2, 121/297 Biochemistry & Molecular Biology | spa |
dc.description.impact | 0.874 SJR (2021) Q1, 587/2489 Medicine (miscellaneous) | spa |
dc.description.impact | No data IDR 2021 | spa |
dc.identifier.doi | 10.3390/biomedicines9040392 | |
dc.rights.accessRights | openAccess | spa |
dc.subject.unesco | Cáncer | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |